Page last updated: 2024-12-07

2,3-bis(4-hydroxyphenyl)-propionitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-bis(4-hydroxyphenyl)-propionitrile: a selective estrogen receptor beta agonist or modulator. also called DPN compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,3-bis(4-hydroxyphenyl)propionitrile : A nitrile that is acetonitrile in which one of the hydrogens is replaced by a 4-hydroxyphenyl group while a second hydrogen is replaced by a 4-hydroxybenzyl group. It is a specific agonist for estrogen receptor beta (ERbeta). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID102614
CHEMBL ID334773
CHEBI ID63949
SCHEMBL ID1940848
MeSH IDM0466664

Synonyms (43)

Synonym
HMS3267P04
BRD-A27143604-001-01-2
2,3-bis(p-hydroxyphenyl)propionitrile
2,3-bis(4-hydroxyphenyl)propanenitrile
diarylpropionitrile
dpn compound
2,3-bis(4-hydroxyphenyl)-propionitrile
gtpl2825
CHEMBL334773 ,
chebi:63949 ,
2,3-bis-(4-hydroxy-phenyl)-propionitrile
bdbm50106635
(+/-)-2,3-bis(4-hydroxyphenyl)propanenitrile
52xwb8q4v8 ,
propionitrile, 2,3-bis(p-hydroxyphenyl)-
1428-67-7
unii-52xwb8q4v8
2,3-bis(p-hydroxyphenyl)-propionitrile
2,3-bis(4-hydroxyphenyl)propionitrile
c15h13no2
AKOS022488638
benzenepropanenitrile,4-hydroxy-a-(4-hydroxyphenyl)-
SCHEMBL1940848
CS-3514
HB2489
HY-12452
HMS3650I14
B4385
DTXSID0040387
mfcd01695412
SR-01000597601-1
sr-01000597601
2,3-bis(4-hydroxyphenyl)propionitrile, >=98% (hplc)
J-007709
HMS3678M03
Q25100751
SR-01000597601-2
HMS3414M03
AMF0011
D89075
AS-76308
benzenepropanenitrile, 4-hydroxy-.alpha.-(4-hydroxyphenyl)-
4-hydroxy-.alpha.-(4-hydroxyphenyl)benzenepropanenitrile

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic properties of DPN and PPT reported could facilitate experimental designs requiring specified levels of receptor occupancy for quantitative comparisons of ER subtype specificities for natural and synthetic estrogens in vivo."( Pharmacokinetics of the estrogen receptor subtype-selective ligands, PPT and DPN: quantification using UPLC-ES/MS/MS.
Churchwell, MI; Doerge, DR; Katzenellenbogen, JA; Korol, DL; Lebl-Rinnova, M; Mann, MK; Pisani, SL; Sepehr, E, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" In addition to providing evidence suggesting the potential use of ERβ agonists in combination with letrozole in treating AI resistant breast cancer and prolonging sensitivity to AI, we also provide mechanistic evidence supporting the role of ERβ in altering the expression profile associated with resistance."( Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
Ganapathy, M; Kirma, NB; Nair, HB; Tekmal, RR; Vadlamudi, RK, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" Ingested BCA is known to display low bioavailability due to poor solubility, extensive metabolism and rapid clearance."( Ester and carbamate ester derivatives of Biochanin A: synthesis and in vitro evaluation of estrogenic and antiproliferative activities.
Alexi, X; Alexis, MN; Aligiannis, N; Fokialakis, N; Meligova, AK; Mitakou, S; Pratsinis, H; Siriani, D, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
"Assessing for interactions among chemicals in a mixture involves the comparison of actual mixture responses to those predicted under the assumption of zero interaction (additivity), based on individual chemical dose-response data."( A novel flexible approach for evaluating fixed ratio mixtures of full and partial agonists.
Carchman, RA; Carney, EW; Carter, WH; Charles, GD; Gennings, C; Gollapudi, BB, 2004
)
0.32
"Although 17beta-estradiol (estrogen) and estrogen receptor (ER) agonist administration after trauma-hemorrhage improves cardiac function, it remains unknown what the optimal estrogen or ER agonist dosage is to elicit this beneficial effect."( Systematic analysis of the salutary effect of estrogen on cardiac performance after trauma-hemorrhage.
Ba, ZF; Chaudry, IH; Chen, J; Hsu, JT; Kan, WH; Schwacha, MG, 2008
)
0.35
" Endothelium-dependent and -independent vasorelaxation were measured by generating dose-response curves to acetylcholine (10(-8)M - 10(-4)M) and sodium nitroprusside (10(-9)M - 10(-5)M)."( Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism.
Crisostomo, PR; Lahm, T; Markel, TA; Meldrum, DR; Tan, J; Wang, M; Wang, Y, 2008
)
0.35
" All drugs were administered once daily for 4 days prior to testing as this dosing paradigm has previously been used to demonstrate anxiolytic effects of DPN in virgin rats."( Reproductive experience modifies the effects of estrogen receptor alpha activity on anxiety-like behavior and corticotropin releasing hormone mRNA expression.
Bridges, RS; Byrnes, EM; Casey, K, 2012
)
0.38
" A dose-response paradigm was used, with each compound tested at 4 different doses in separate groups of rats."( Estrogen Receptor-Selective Agonists Modulate Learning in Female Rats in a Dose- and Task-Specific Manner.
Katzenellenbogen, JA; Korol, DL; Neese, SL; Pisani, SL; Schantz, SL, 2016
)
0.43
" These observations suggest that a physiological dosage of E2 reduces depressive behavior and enhances TPH expression."( Physiological dosages of estradiol and diarylpropionitrile decrease depressive behavior and increase tryptophan hydroxylase expression in the dorsal raphe nucleus of rats subjected to the forced swim test.
Cheung, A; Sheng, J; Tao, J; Wan, W; Yang, F; Zhao, N, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
estrogen receptor agonistAn agonist at the estrogen receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)EC50 (µMol)1.62470.00000.53054.4000AID1410191; AID1573132; AID1573133; AID1713771; AID223390; AID436349; AID644918; AID644923; AID644928; AID645559
Cytochrome P450 2C9 Homo sapiens (human)EC50 (µMol)2.30000.00080.41702.3000AID1573132
Estrogen receptor betaHomo sapiens (human)EC50 (µMol)115.71830.00000.47954.8900AID1410193; AID1573114; AID1573115; AID1573131; AID1594603; AID1594604; AID1713770; AID1855802; AID436350; AID644916; AID644921; AID644926; AID645557; AID70021
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (58)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID1573115Binding affinity to human GST-tagged estrogen receptor beta ligand binding domain after 1 hr by TR-FRET assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1594606Activation of human ERbeta assessed as induction of transcriptional activation incubated for 24 hrs in presence of 100 uM H2O2 by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID70021Transcriptional potency (EC50) at Human estrogen receptor Beta2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID1410195Selectivity ratio of EC50 for ERalpha in human Ishikawa cells to EC50 for ERbeta (unknown origin) expressed in human MDA-MB-231/beta41 cells2018Journal of natural products, 04-27, Volume: 81, Issue:4
Estrogen Receptor (ER) Subtype Selectivity Identifies 8-Prenylapigenin as an ERβ Agonist from Glycyrrhiza inflata and Highlights the Importance of Chemical and Biological Authentication.
AID644919Agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERalpha ligand binding domain expressed in Escherichia coli BL21 cells after 1 hr by TR-FRET assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID436351Selectivity ratio of EC50 for ERbeta to EC50 for ERalpha expressed in human HEC1 cells2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID644922Agonist activity at human N-His6-tagged terbium-labelled ERbeta ligand binding domain expressed in Escherichia coli BL21 cells assessed as recruitment of fluorescein-labelled SRC3 after 1 hr by TR-FRET assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID471327Displacement of fluorescent estrogen ES2 from human recombinant ERbeta by fluorescence polarization assay relative to 17-beta-estradiol2009Journal of natural products, Sep, Volume: 72, Issue:9
Isoflavonoids from Erythrina poeppigiana: evaluation of their binding affinity for the estrogen receptor.
AID231690Ratio between Relative estrogenic potency of hER beta and ERalpha2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID1573184Memory enhancement effect in C57BL/6 mouse assessed as time spent with moved object at 0.05 mg/kg, po administered via gavage by object recognition test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1573140Memory enhancement effect in C57BL/6 mouse assessed as time spent with moved object at 10 pg administered as dorsal hippocampal infusion by novel object recognition test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID397676Activity at ERbeta in human MCF7 cells assessed as change in c-myc protein level at 1 uM after 12 hrs by Western blot analysis relative to actin2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID1573172Cardiotoxicity in ovariectomized C57BL/6 mouse assessed as myofiber disarray at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1410191Estrogenic activity at ERalpha in human Ishikawa cells assessed as induction of alkaline phosphatase activity using p-nitrophenol as substrate treated for 96 hrs followed by substrate addition by spectrophotometric method2018Journal of natural products, 04-27, Volume: 81, Issue:4
Estrogen Receptor (ER) Subtype Selectivity Identifies 8-Prenylapigenin as an ERβ Agonist from Glycyrrhiza inflata and Highlights the Importance of Chemical and Biological Authentication.
AID1855802Agonist activity at human ER-beta transfected in HEC-1 cells assessed as transcriptional activation incubated for 24 hrs by dual luciferase reporter assay2022European journal of medicinal chemistry, Nov-05, Volume: 241An overview on Estrogen receptors signaling and its ligands in breast cancer.
AID223392Relative estrogenic potency at Human estrogen receptor alpha (EC50 (Estradiol) / EC50 (ligand))2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID223391Relative binding affinity (RBA) at Human estrogen receptor alpha (radiometric binding assay with [3H]estradiol using full-length human ER alpha)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID644915Selectivity ratio of binding affinity to human N-His6-tagged human ERbeta relative to estradiol to binding affinity for human N-His6-tagged ERalpha relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID645560Agonist activity at human ERalpha expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573114Antagonist activity at estrogen receptor beta (unknown origin) assessed as inhibition of estradiol-induced response after 22 hrs by cell-based luciferase reporter gene assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1573131Agonist activity at estrogen receptor beta (unknown origin) after 22 hrs by cell-based luciferase reporter gene assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1573179Hepatotoxicity in ovariectomized C57BL/6 mouse assessed as intact hepatic arteries at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID350857Displacement of [3H]estradiol from full-length human estrogen receptor alpha assessed as relative binding affinity by radiometric assay relative to estradiol2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis and evaluation of aryl-substituted diarylpropionitriles, selective ligands for estrogen receptor beta, as positron-emission tomographic imaging agents.
AID1410192Estrogenic activity at ERalpha in human Ishikawa cells assessed as induction of alkaline phosphatase activity using p-nitrophenol as substrate treated for 96 hrs followed by substrate addition by spectrophotometric method relative to estradiol2018Journal of natural products, 04-27, Volume: 81, Issue:4
Estrogen Receptor (ER) Subtype Selectivity Identifies 8-Prenylapigenin as an ERβ Agonist from Glycyrrhiza inflata and Highlights the Importance of Chemical and Biological Authentication.
AID1573177Renal toxicity in ovariectomized C57BL/6 mouse assessed as inflammation at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1573134Selectivity ratio of EC50 for estrogen receptor alpha (unknown origin) to EC50 for estrogen receptor beta (unknown origin)2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID436348Selectivity ratio of relative transcription potency for ERbeta to relative transcription potency for ERalpha expressed in human HEC1 cells2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID645557Agonist activity at human ERbeta expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1713770Agonist activity at human ERbeta receptor expressed in HEK293T cells transfected with pGL4.27-(ERE)3-Luc assessed as transcriptional activation measured after 16 hrs by Dual-Glo luciferase assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta.
AID644920Selectivity ratio of agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERbeta LBD relative to estradiol to agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERalpha LBD relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1594596Retention time of the compound at 150 uM by HPLC analysis2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID436344Displacement of [3H]estradiol from human full length ERbeta relative binding affinity by competitive radiometric binding assay relative to estradiol2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID471330Selectivity ratio of IC50 for human recombinant ERalpha to IC50 for human recombinant ERbeta2009Journal of natural products, Sep, Volume: 72, Issue:9
Isoflavonoids from Erythrina poeppigiana: evaluation of their binding affinity for the estrogen receptor.
AID436343Displacement of [3H]estradiol from human full length ERalpha assessed as relative binding affinity by competitive radiometric binding assay relative to estradiol2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID644917Agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERbeta ligand binding domain expressed in Escherichia coli BL21 cells after 1 hr by TR-FRET assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID436346Agonist activity at ERalpha expressed in human HEC1 cells assessed as relative transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay relative to estradiol2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID1410194Estrogenic activity at ERbeta (unknown origin) expressed in human MDA-MB-231/beta41 cells after 18 hrs by renilla luciferase reporter gene assay relative to estradiol2018Journal of natural products, 04-27, Volume: 81, Issue:4
Estrogen Receptor (ER) Subtype Selectivity Identifies 8-Prenylapigenin as an ERβ Agonist from Glycyrrhiza inflata and Highlights the Importance of Chemical and Biological Authentication.
AID1594603Activation of human ERbeta assessed as induction of transcriptional activation incubated for 24 hrs by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID644921Agonist activity at human N-His6-tagged terbium-labelled ERbeta ligand binding domain expressed in Escherichia coli BL21 cells assessed as recruitment of fluorescein-labelled SRC3 after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID397679Selectivity for ERbeta over ERalpha2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID1573169Cardiotoxicity in ovariectomized C57BL/6 mouse assessed as ventricular walls with normal thickness at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1594583Displacement of fluormone tracer from full length human recombinant ERalpha incubated for 2 hrs by competitive fluorescence polarization binding assay relative to estradiol2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID1713776Ratio of 17beta-estradiol EC50 to test compound EC50 for human ERbeta expressed in HEK293T cells to 17beta-estradiol EC50 to test compound EC50 for human ERalpha expressed in HEK293T cells2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta.
AID1573181Effect on cell proliferation of human MCF7 cells at 10 to 1000 nM after 24 hrs by MTT assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID644928Agonist activity at human ERalpha expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573143Memory enhancement effect in C57BL/6 mouse assessed as time spent with novel object at 10 pg administered as dorsal hippocampal infusion by novel object recognition test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID397677Activity at ERbeta in human MCF7 cells assessed as change in p21 protein level at 1 uM after 12 hrs by Western blot analysis relative to actin2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID1573168Cardiotoxicity in ovariectomized C57BL/6 mouse assessed as intact ventricular walls at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1594605Activation of human ERbeta assessed as induction of transcriptional activation incubated for 24 hrs in presence of 50 uM H2O2 by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID645562Selectivity ratio of agonist activity at human Erbeta expressed in HEC-1 cells to agonist activity at human Eralpha expressed in HEC-1 cells2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573174Cardiotoxicity in ovariectomized C57BL/6 mouse assessed as ischemic injury at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID436350Agonist activity at ERbeta expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID658953Displacement of fluorescent estrogen ES2 from recombinant ERalpha receptor by fluorescence polarization assay relative to estradiol2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Ester and carbamate ester derivatives of Biochanin A: synthesis and in vitro evaluation of estrogenic and antiproliferative activities.
AID645561Selectivity ratio of agonist activity at human ERbeta expressed in U2OS cells relative to estradiol to agonist activity at human ERalpha expressed in U2OS cells relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID644926Agonist activity at human ERbeta expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID223390Transcriptional potency (EC50) at Human estrogen receptor alpha2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID645555Agonist activity at human ERalpha expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573176Renal toxicity in ovariectomized C57BL/6 mouse assessed as normal tubules at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID436349Agonist activity at ERalpha expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID644918Agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERalpha ligand binding domain expressed in Escherichia coli BL21 cells after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID658954Displacement of fluorescent estrogen ES2 from recombinant ERbeta receptor by fluorescence polarization assay relative to estradiol2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Ester and carbamate ester derivatives of Biochanin A: synthesis and in vitro evaluation of estrogenic and antiproliferative activities.
AID1594604Activation of human ERbeta assessed as induction of transcriptional activation by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID645556Selectivity ratio of agonist activity at human ERbeta expressed in HEC-1 cells relative to estradiol to agonist activity at human ERalpha expressed in HEC-1 cells relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573190Toxicity in ovariectomized C57BL/6 mouse assessed as effect on hematology parameters at 0.05 mg/kg, ip administered as single dose after 24 hrs2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID350856Displacement of [3H]estradiol from full-length human estrogen receptor beta assessed as relative binding affinity by radiometric assay relative to estradiol2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis and evaluation of aryl-substituted diarylpropionitriles, selective ligands for estrogen receptor beta, as positron-emission tomographic imaging agents.
AID1573183Memory enhancement effect in C57BL/6 mouse assessed as time spent with novel object at 0.05 mg/kg, ip by novel object recognition test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1573186Memory enhancement effect in ovariectomized C57BL/6 mouse at 0.05 mg/kg, po administered via gavage after 1 to 4 months within ovariectomy by novel object recognition test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID350858Selectivity ratio of relative binding affinity for full-length human estrogen receptor beta to ratio of relative binding affinity for full length human estrogen receptor alpha2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis and evaluation of aryl-substituted diarylpropionitriles, selective ligands for estrogen receptor beta, as positron-emission tomographic imaging agents.
AID1573180Hepatotoxicity in ovariectomized C57BL/6 mouse assessed as normal central veins at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID436345Selectivity for human ERbeta receptor over human ERalpha receptor2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID1573132Agonist activity at estrogen receptor alpha (unknown origin) after 22 hrs by cell-based luciferase reporter gene assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1713772Binding affinity to full length human ERalpha receptor expressed in insect cells by fluorescence polarization assay relative to 17beta-estradiol2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta.
AID644923Agonist activity at human N-His6-tagged terbium-labelled ERalpha ligand binding domain expressed in Escherichia coli BL21 cells assessed as recruitment of fluorescein-labelled SRC3 after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573185Memory enhancement effect in C57BL/6 mouse assessed as time spent with novel object at 0.05 mg/kg, po administered via gavage by novel object recognition test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1573133Antagonist activity at estrogen receptor alpha (unknown origin) assessed as inhibition of estradiol-induced response after 22 hrs by cell-based luciferase reporter gene assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID70170Relative binding affinity (RBA) at human estrogen receptor beta (radiometric binding assay with [3H]estradiol using full-length human ER Beta)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID471326Displacement of fluorescent estrogen ES2 from human recombinant ERalpha by fluorescence polarization assay relative to 17-beta-estradiol2009Journal of natural products, Sep, Volume: 72, Issue:9
Isoflavonoids from Erythrina poeppigiana: evaluation of their binding affinity for the estrogen receptor.
AID1713774Selectivity ratio of relative binding affinity for full length human ERbeta expressed in insect cells by fluorescence polarization assay to relative binding affinity for full length human ERalpha expressed in insect cells by fluorescence polarization assa2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta.
AID645558Agonist activity at human ERbeta expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573170Cardiotoxicity in ovariectomized C57BL/6 mouse assessed as intact atrial walls at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID644913Displacement of [3H]17betaE2 from human N-His6-tagged ERbeta ligand binding domain expressed in Escherichia coli BL21 cells by radiometric assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573173Cardiotoxicity in ovariectomized C57BL/6 mouse assessed as ischemic heart disease at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID644925Selectivity ratio of agonist activity at human N-His6-tagged terbium-labelled human ERbeta relative to estradiol to agonist activity at human N-His6-tagged terbium-labelled ERalpha relative to estradiol assessed as recruitment of fluorescein-labelled SRC32012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID70174Relative estrogenic potency at Human estrogen receptor Beta (EC50 (Estradiol) / EC50 (ligand))2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID1713771Agonist activity at human ERalpha receptor expressed in HEK293T cells transfected with pGL4.27-(ERE)3-Luc assessed as transcriptional activation measured after 16 hrs by Dual-Glo luciferase assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta.
AID1410193Estrogenic activity at ERbeta (unknown origin) expressed in human MDA-MB-231/beta41 cells after 18 hrs by renilla luciferase reporter gene assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Estrogen Receptor (ER) Subtype Selectivity Identifies 8-Prenylapigenin as an ERβ Agonist from Glycyrrhiza inflata and Highlights the Importance of Chemical and Biological Authentication.
AID645559Agonist activity at human ERalpha expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID644924Agonist activity at human N-His6-tagged terbium-labelled ERalpha ligand binding domain expressed in Escherichia coli BL21 cells assessed as recruitment of fluorescein-labelled SRC3 after 1 hr by TR-FRET assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573182Memory enhancement effect in C57BL/6 mouse assessed as time spent with moved object at 0.05 mg/kg, ip by novel object recognition test2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID436347Agonist activity at ERbeta expressed in human HEC1 cells assessed as relative transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay relative to estradiol2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.
AID1573171Cardiotoxicity in ovariectomized C57BL/6 mouse assessed as atrial walls with normal thickness at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID644916Agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERbeta ligand binding domain expressed in Escherichia coli BL21 cells after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1594584Displacement of fluormone tracer from full length human recombinant ERbeta incubated for 2 hrs by competitive fluorescence polarization binding assay relative to estradiol2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID397678Activity at ERbeta in human MCF7 cells assessed as change in p27 protein level at 1 uM after 12 hrs by Western blot analysis relative to actin2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.
AID1573175Renal toxicity in ovariectomized C57BL/6 mouse assessed as intact glomeruli at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID231688Ratio between RBA% values of hER beta an d ERalpha2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID644914Displacement of [3H]17betaE2 from human N-His6-tagged ERalpha ligand binding domain expressed in Escherichia coli BL21 cells by radiometric assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1573178Hepatotoxicity in ovariectomized C57BL/6 mouse assessed as intact hepatic ducts at 0.05 mg/kg, ip administered as single dose after 24 hrs by hematoxylin and eosin staining-based assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID1573189Toxicity in ovariectomized C57BL/6 mouse assessed as effect on blood work chemistry parameters at 0.05 mg/kg, ip administered as single dose after 24 hrs2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions.
AID231465Ratio between EC50 values of hER beta and ERalpha2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
AID1713773Binding affinity to full length human ERbeta receptor expressed in insect cells by fluorescence polarization assay relative to 17beta-estradiol2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta.
AID644927Agonist activity at human ERbeta expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay relative to estradiol2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)2009Brain research, Sep-22, Volume: 1290Estrogen receptor alpha and beta specific agonists regulate expression of synaptic proteins in rat hippocampus.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)2009Brain research, Sep-22, Volume: 1290Estrogen receptor alpha and beta specific agonists regulate expression of synaptic proteins in rat hippocampus.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (278)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's98 (35.25)29.6817
2010's166 (59.71)24.3611
2020's14 (5.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.27 (24.57)
Research Supply Index5.64 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (0.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other279 (99.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]